Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

Arthritis and Rheumatism

Volumn 56, Issue 12, 2007, Pages 4142-4150

  Dall'Era, Maria ^a   Chakravarty, Eliza ^b   Wallace, Daniel ^c   Genovese, Mark ^b   Weisman, Michael ^c   Kavanaugh, Arthur ^d   Kalunian, Kenneth ^d   Dhar, Patricia ^e   Vincent, Emmanuelle ^f   Pena Rossi, Claudia ^f   Wofsy, David ^a   Alum, Nasreen ^f   Dubois, Annette ^f   Kinnman, Nils ^f   Picard, Marie ^f   Bortolotti, Alessandro ^g   O'Grady, Laura ^h   Hill, Julieann ⁱ   Nestorov, Ivan ⁱ   Salmon, Elisabeth ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f Serono International SA   (Switzerland)

^g Industria Farmaceutica Serono Spa   (Italy)

^h EMD Serono   (United States)

ⁱ ZYMOGENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATACICEPT; AZATHIOPRINE; CORTICOSTEROID; CORTICOTROPIN; IBUPROFEN; IMMUNOGLOBULIN; PARACETAMOL; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; B LYMPHOCYTE; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEART VENTRICLE BIGEMINY; HUMAN; INJECTION SITE REACTION; MALE; MOUTH ULCER; MULTICENTER STUDY; NATURAL KILLER CELL; NAUSEA; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME PROLONGATION; RASH; REPEATED DRUG DOSE; RHINITIS; SCORING SYSTEM; SINUSITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VAGINA MYCOSIS;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; B-LYMPHOCYTES; CELL PROLIFERATION; COMPLEMENT C3; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RNA, DOUBLE-STRANDED;

EID: 37149032474     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23047     Document Type: Article

References (28)

1. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006;5: 564-76.
2. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
3. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
4. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5.
5. Dorner T, Kaufman J, Wegener WA, Teoh N, Goldenberg DM, Burmestcr GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74.
6. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65.
7. Wallace DJ, Lisse J, Stohl W, McKay J, Boling E, Merrill JT, et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks [abstract]. Arthritis Rheum 2006;54 Suppl 9:S790.
8. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302.
9. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54.
10. Luger D, Dayan M, Zinger H, Liu JP, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004;24:579-90.
11. Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 2004;137:513-20.
12. Gross JA, Johnston J, Mudri S, Enselman R, Dillon S, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000:404:995-9.
13. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710.
14. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 2000;97:3370-5.
15. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005;52:2080-91.
16. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
17. Cheema GS, Roschke V, Hubert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9.
18. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86.
19. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065-7.
20. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003;48:982-92.
21. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006;116:724-34.
22. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
23. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
24. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
25. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al, for the OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353;2550-8.
26. Cancer Therapy Evaluation Program: Common Toxicity Criteria version 2.0 (CTC). Bethesda (MD): Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 1999.
27. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000;27:377-9.
28. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5:235-46.